AtonRa Partners Sells 736 Shares of Axonics, Inc. (NASDAQ:AXNX)

AtonRa Partners lessened its stake in Axonics, Inc. (NASDAQ:AXNX) by 8.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 8,097 shares of the company’s stock after selling 736 shares during the quarter. AtonRa Partners’ holdings in Axonics were worth $504,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. FMR LLC boosted its holdings in shares of Axonics by 71.8% in the 3rd quarter. FMR LLC now owns 4,558,444 shares of the company’s stock valued at $255,820,000 after buying an additional 1,904,955 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Axonics by 5.8% in the 3rd quarter. Invesco Ltd. now owns 1,634,984 shares of the company’s stock valued at $91,755,000 after buying an additional 90,132 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Axonics by 0.9% in the 4th quarter. Mackenzie Financial Corp now owns 1,250,005 shares of the company’s stock valued at $77,788,000 after buying an additional 10,872 shares during the last quarter. Artisan Partners Limited Partnership acquired a new stake in shares of Axonics in the 3rd quarter valued at approximately $35,745,000. Finally, Kennedy Capital Management LLC boosted its holdings in shares of Axonics by 74.0% in the 3rd quarter. Kennedy Capital Management LLC now owns 399,970 shares of the company’s stock valued at $22,446,000 after buying an additional 170,068 shares during the last quarter. Institutional investors and hedge funds own 99.48% of the company’s stock.

Axonics Trading Up 0.4 %

AXNX stock traded up $0.24 during trading hours on Monday, hitting $66.93. 656,211 shares of the stock were exchanged, compared to its average volume of 1,242,642. The firm has a market capitalization of $3.41 billion, a P/E ratio of -514.85 and a beta of 0.56. The company has a 50-day simple moving average of $67.90 and a two-hundred day simple moving average of $62.84. Axonics, Inc. has a 12 month low of $47.59 and a 12 month high of $69.68.

Axonics (NASDAQ:AXNX) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.07. The firm had revenue of $109.70 million for the quarter, compared to analysts’ expectations of $107.33 million. Axonics had a negative return on equity of 1.00% and a negative net margin of 1.66%. The company’s quarterly revenue was up 27.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.01 EPS. On average, equities research analysts predict that Axonics, Inc. will post 0.32 earnings per share for the current year.

Analysts Set New Price Targets

AXNX has been the subject of several recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Axonics in a report on Wednesday, January 17th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $71.00 price target (up previously from $68.00) on shares of Axonics in a report on Wednesday, January 10th. Truist Financial reaffirmed a “hold” rating and set a $71.00 price target (down previously from $73.00) on shares of Axonics in a report on Friday, January 12th. Piper Sandler reaffirmed a “neutral” rating and set a $71.00 price target (down previously from $75.00) on shares of Axonics in a report on Friday, January 12th. Finally, Wolfe Research downgraded Axonics from an “outperform” rating to a “peer perform” rating in a report on Tuesday, January 9th. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $70.73.

Insiders Place Their Bets

In related news, insider Karen Noblett sold 11,288 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $764,649.12. Following the transaction, the insider now owns 34,428 shares in the company, valued at $2,332,152.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Raymond W. Cohen sold 35,161 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $2,381,806.14. Following the completion of the transaction, the chief executive officer now owns 188,835 shares of the company’s stock, valued at $12,791,682.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Karen Noblett sold 11,288 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $764,649.12. Following the transaction, the insider now directly owns 34,428 shares of the company’s stock, valued at approximately $2,332,152.72. The disclosure for this sale can be found here. Insiders have sold 65,837 shares of company stock worth $4,459,798 in the last 90 days. Company insiders own 1.85% of the company’s stock.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.